Xilio Therapeutics (XLO) Analyst & Key Data

Analyst Consensus

Analyst recommendation mix is not available yet.

Total Analysts0

Ratings

Updated Sep 12, 2026

Overall Rating

B-

DCF Score5.0 / 5

Debt / Equity Score3.0 / 5

Price / Book Score3.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$8.93

Median Target-100.00%

$0.00

Potential downside vs current price

DCF Value+250.82%

$31.33

Potential upside vs current price

Current Stock Price

$8.93

Median Target-100.00%

$0.00

Potential downside vs current price

DCF Value+250.82%

$31.33

Potential upside vs current price

Analyst Consensus

Analyst recommendation mix is not available yet.

Total Analysts0

Ratings

Updated Sep 12, 2026

Overall Rating

B-

DCF Score5.0 / 5

Debt / Equity Score3.0 / 5

Price / Book Score3.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$8.93

Median Target-100.00%

$0.00

Potential downside vs current price

DCF Value+250.82%

$31.33

Potential upside vs current price

Current Stock Price

$8.93

Median Target-100.00%

$0.00

Potential downside vs current price

DCF Value+250.82%

$31.33

Potential upside vs current price

Xilio Therapeutics, Inc.